{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=tazarotene",
    "query": {
      "intervention": "tazarotene"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 48,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=tazarotene&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-10T02:23:53.018Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00489086",
      "title": "Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neoplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "tazarotene",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UCSF Benioff Children's Hospital Oakland",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 36,
      "start_date": "2004-07",
      "completion_date": "2012-06",
      "has_results": true,
      "last_update_posted_date": "2020-10-29",
      "last_synced_at": "2026-09-10T02:23:53.018Z",
      "location_count": 2,
      "location_summary": "Oakland, California • New York, New York",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00489086"
    },
    {
      "nct_id": "NCT03599193",
      "title": "A Bioavailability Study of DFD-03 Compared to Tazorac® in Patients With Moderate Acne Vulgaris",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "Tazarotene Lotion, 0.1%",
          "type": "DRUG"
        },
        {
          "name": "Tazarotene Cream, 0.1%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dr. Reddy's Laboratories Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "9 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "9 Years and older"
      },
      "enrollment_count": 58,
      "start_date": "2017-10-04",
      "completion_date": "2018-04-30",
      "has_results": true,
      "last_update_posted_date": "2021-03-01",
      "last_synced_at": "2026-09-10T02:23:53.018Z",
      "location_count": 2,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03599193"
    },
    {
      "nct_id": "NCT00834210",
      "title": "Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne Vulgaris",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "Dapsone",
          "type": "DRUG"
        },
        {
          "name": "Tazarotene",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 171,
      "start_date": "2008-12",
      "completion_date": "2009-09",
      "has_results": true,
      "last_update_posted_date": "2011-10-31",
      "last_synced_at": "2026-09-10T02:23:53.018Z",
      "location_count": 1,
      "location_summary": "Fremont, California",
      "locations": [
        {
          "city": "Fremont",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00834210"
    },
    {
      "nct_id": "NCT03168321",
      "title": "A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (301)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "IDP-123 Lotion",
          "type": "DRUG"
        },
        {
          "name": "IDP-123 Vehicle Lotion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch Health Americas, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "9 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "9 Years to 99 Years"
      },
      "enrollment_count": 813,
      "start_date": "2017-06-29",
      "completion_date": "2018-06-07",
      "has_results": true,
      "last_update_posted_date": "2021-04-01",
      "last_synced_at": "2026-09-10T02:23:53.018Z",
      "location_count": 42,
      "location_summary": "Phoenix, Arizona • Hot Springs, Arkansas • La Mesa, California + 37 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Manhattan Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03168321"
    },
    {
      "nct_id": "NCT05203315",
      "title": "Investigator Initiated Trial to Study Duobrii® Lotion in the Treatment of Mild Plaque Psoriasis in Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Plaque Psoriasis"
      ],
      "interventions": [
        {
          "name": "Duobrii 0.01 % / 0.045 % Topical Lotion",
          "type": "DRUG"
        },
        {
          "name": "CeraVe, Topical Cream",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Austin Institute for Clinical Research",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 21,
      "start_date": "2022-01-13",
      "completion_date": "2023-10-04",
      "has_results": false,
      "last_update_posted_date": "2024-07-19",
      "last_synced_at": "2026-09-10T02:23:53.018Z",
      "location_count": 2,
      "location_summary": "Houston, Texas • Pflugerville, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Pflugerville",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05203315"
    },
    {
      "nct_id": "NCT01017120",
      "title": "A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "Tazarotene Foam",
          "type": "DRUG"
        },
        {
          "name": "Vehicle Foam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stiefel, a GSK Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "12 Years to 45 Years"
      },
      "enrollment_count": 742,
      "start_date": "2009-10-01",
      "completion_date": "2010-11-09",
      "has_results": true,
      "last_update_posted_date": "2017-05-18",
      "last_synced_at": "2026-09-10T02:23:53.018Z",
      "location_count": 14,
      "location_summary": "Santa Monica, California • Miami, Florida • Alpharetta, Georgia + 11 more",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Alpharetta",
          "state": "Georgia"
        },
        {
          "city": "Snellville",
          "state": "Georgia"
        },
        {
          "city": "Evansville",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01017120"
    },
    {
      "nct_id": "NCT01019603",
      "title": "A Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects With Acne Vulgaris",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "Tazarotene",
          "type": "DRUG"
        },
        {
          "name": "Tazaroc Gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stiefel, a GSK Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2009-10-12",
      "completion_date": "2009-12-20",
      "has_results": false,
      "last_update_posted_date": "2017-06-23",
      "last_synced_at": "2026-09-10T02:23:53.018Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01019603"
    },
    {
      "nct_id": "NCT00469755",
      "title": "Differin® Gel x12 Wks vs Tazorac® Cream x12 Wks vs Differin® x6 Wks Switched to Tazorac® x6 Wks for Treatment of Acne",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "Adapalene Gel, 0.1%",
          "type": "DRUG"
        },
        {
          "name": "Tazarotene Cream, 0.1%",
          "type": "DRUG"
        },
        {
          "name": "Adapalene Gel, 0.1% + Tazarotene Cream, 0.1%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Galderma R&D",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "12 Years to 35 Years"
      },
      "enrollment_count": 302,
      "start_date": "2006-02",
      "completion_date": "2006-09",
      "has_results": false,
      "last_update_posted_date": "2022-07-29",
      "last_synced_at": "2026-09-10T02:23:53.018Z",
      "location_count": 12,
      "location_summary": "San Diego, California • Detroit, Michigan • Fridley, Minnesota + 9 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Fridley",
          "state": "Minnesota"
        },
        {
          "city": "Brooklyn",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00469755"
    },
    {
      "nct_id": "NCT02849873",
      "title": "Absorption and Systematic Pharmacokinetics of IDP-123 Lotion in Comparison With Tazorac Cream",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acne"
      ],
      "interventions": [
        {
          "name": "IDP-123 Lotion",
          "type": "DRUG"
        },
        {
          "name": "Tazorac Cream",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch Health Americas, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "9 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "9 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2016-06",
      "completion_date": "2017-01",
      "has_results": false,
      "last_update_posted_date": "2018-07-19",
      "last_synced_at": "2026-09-10T02:23:53.018Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02849873"
    },
    {
      "nct_id": "NCT00648986",
      "title": "Efficacy and Safety Study of Tazarotene (Tazorac) for the Treatment of Brittle Nails",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Brittle Nails"
      ],
      "interventions": [
        {
          "name": "Tazorac",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "76 Years",
        "sex": "ALL",
        "summary": "18 Years to 76 Years"
      },
      "enrollment_count": 20,
      "start_date": "2005-08",
      "completion_date": "2006-12",
      "has_results": false,
      "last_update_posted_date": "2014-07-02",
      "last_synced_at": "2026-09-10T02:23:53.018Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00648986"
    }
  ]
}